Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
Authors:
Open Access
- 26 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e66955
Abstract
Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC) activity. We evaluated methods to detect changes in chloride and sodium transport by NPD based on a secondary analysis of a Phase II CFTR-modulator study. Thirty-nine subjects with CF who also had the G551D-CFTR mutation were randomized to receive ivacaftor (Kalydeco™; also known as VX-770) in four doses or placebo twice daily for at least 14 days. All data were analyzed by a single investigator who was blinded to treatment assignment. We compared three analysis methods to determine the best approach to quantify changes in chloride and sodium transport: (1) the average of both nostrils; (2) the most-polarized nostril at each visit; and (3) the most-polarized nostril at screening carried forward. Parameters of ion transport included the PD change with zero chloride plus isoproterenol (CFTR activity), the basal PD, Ringer's PD, and change in PD with amiloride (measurements of ENaC activity), and the delta NPD (measuring CFTR and ENaC activity). The average and most-polarized nostril at each visit were most sensitive to changes in chloride and sodium transport, whereas the most-polarized nostril at screening carried forward was less discriminatory. Based on our findings, NPD studies should assess both nostrils rather than a single nostril. We also found that changes in CFTR activity were more readily detected than changes in ENaC activity, and that rigorous standardization was associated with relatively good within-subject reproducibility in placebo-treated subjects (±2.8 mV). Therefore, we have confirmed an assay of reasonable reproducibility for detecting chloride-transport improvements in response to CFTR modulation.Keywords
This publication has 30 references indexed in Scilit:
- Airway ion transport impacts on disease presentation and severity in cystic fibrosisClinical Biochemistry, 2008
- Sodium Channels and Cystic FibrosisChest, 2007
- The epithelium as a target for therapy in cystic fibrosisCurrent Opinion in Pharmacology, 2007
- Airway Surface Dehydration in Cystic Fibrosis: Pathogenesis and TherapyAnnual Review of Medicine, 2007
- Mutations in the Cystic Fibrosis Transmembrane Regulator Gene and In Vivo Transepithelial PotentialsAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Cystic FibrosisNew England Journal of Medicine, 2005
- Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis**Pediatric Pulmonology, 2002
- Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- In Vivo Nasal Potential Difference: Techniques and Protocols for Assessing Efficacy of Gene Transfer in Cystic FibrosisHuman Gene Therapy, 1995
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989